Jun 11, 2019 / 04:20PM GMT
Robert Patrick Jones - Goldman Sachs Group Inc., Research Division - VP
All right. Good morning, everyone. Welcome to the Charles River session. I'm Bob Jones, and I cover the CROs here at Goldman. Very pleased to introduce Charles River, as you're all well aware, a leading preclinical CRO.
I am joined on stage by David Smith, EVP and CFO of Charles River. David joined in 2014 and was named CFO and EVP of the company in August of 2015. So welcome, David.
David Ross Smith - Charles River Laboratories International, Inc. - Corporate Executive VP & CFO
Thank you.
Questions and Answers:
Robert Patrick Jones - Goldman Sachs Group Inc., Research Division - VPSo I guess we'll just jump right in. I think everybody knows the format. To the extent that you have a question, feel free to raise your hand, we'll get you a microphone.
But I thought for starters, David, good place to begin would just be around biotech funding. I think it's been a pretty incredible innovation cycle, I think most would